Livzon Pharmaceutical reports extensive A-share repurchase program

Livzon Pharmaceutical Group Inc. has submitted its Next Day Disclosure Return as of November 4, 2025, revealing significant activity in its A-share repurchase program. The company, which has H-shares listed on the Exchange (stock code: 01513) and A-shares on the Shenzhen Stock Exchange (stock code: 000513), reported no changes in its H-share capital, maintaining 299,807,117 H-shares as of November 4, 2025.

The bulk of the activity concerns the repurchase of A-shares, with numerous transactions occurring between December 2024 and November 2025 on the Shenzhen Stock Exchange. Repurchases ranged from a low of 1,700 A-shares on August 1, 2025, at RMB41.99 per share, to a high of 561,400 A-shares on January 14, 2025, at RMB35.62 per share. The latest reported repurchase on November 4, 2025, involved 164,700 A-shares at RMB36.43 per share.

Cumulatively, as of November 4, 2025, Livzon Pharmaceutical Group Inc. repurchased a total of 164,700 A-shares on that date, with prices ranging from RMB36.16 to RMB36.71. The aggregate price paid for these specific repurchases was RMB5,999,819. The company also confirmed that all repurchases were made in accordance with Main Board Rules and domestic rules, with no material changes to its Explanatory Statement dated April 24, 2025.